Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ULTA +1.8% (Q4 guidance update; new CEO), LNN +0.7%
Other news:
- GETY +76.7% (Shutterstock and Getty Images (GETY) to combine in merger of equals)
- SSTK +43.1% (Shutterstock and Getty Images (GETY) to combine in merger of equals)
- IMRX +31.4% (Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104)
- NARI +21.3% (to be acquired by SYK for $4.9 bln)
- MPTI +7.5% ($10 mln U.S. DoD order)
- ENVX +7.1% (announced the successful completion of Site Acceptance Testing (SAT) for its High Volume Manufacturing (HVM) line at Fab2 in Malaysia)
- ZEPP +4.8% (to Showcase Groundbreaking Innovations at CES Pepcom & ShowStoppers Media Events)
- AEVA +4.1% (introduces Atlas Ultra at CES)
- KALU +3.9% (appoints new CEO)
- INMB +3.9% (receives FDA orphan designation for treatment of epidermolysis bullosa)
- GFL +3.6% (agrees to sell Environmental Services business valued at $8.0 billion)
- LAC +3.5% (increases mineral resource and reserve for Thacker Pass; announces appointment of Luke Colton as EVP and CFO)
- NVX +3.2% (purchases land for future manufacturing plant)
- RAIL +3.2% (to redeem all preferred shares)
- NVDA +2.6% (several CES announcements/updates)
- UBER +2.2% (collaborates with NVIDIA (NVDA) to accelerate autonomous mobility)
- ADC +2% (summarizes 2024 investment activity; provides investment volume guidance)
- SYM +1.8% (appoints new CTO)
- DSX +1.6% (reports final results of self tender offer of common stock)
- MBX +1.4% (Phase 1 Topline Results for MBX 1416)
- LCID +1.2% (to leverage Panasonic Energy's latest-generation high-performance EV Batteries; UAW says Lucid workers win substantial back pay and reinstatement in dramatic settlement)
- SU +1.2% (reports Q4 operational/production results)
- BWXT +1.1% (enters into an agreement to acquire Kinectrics for approximately $525 million, including assumption of Kinectrics' net pension and debt liabilities, and estimated transaction expenses)
- PDS +1% (meets 2024 debt repayment; provides financial and operational updates)
- TECH +1% (prevailed on another claim that Miltenyi Biotec commercialized antibodies developed based on information obtained by reverse engineering its proprietary R&D systems)